In 2023, the U.S. confronted nearly 2 million new cancer cases and over 600,000 deaths. We need better treatments. Advancements in precision medicine, including targeted therapy and immunotherapy, show promise, but the challenges of genetic variation, tumor heterogeneity, and treatment resistance limit therapeutic benefit to a fraction of cancer patients. The lack of reliable predictive immunotherapy markers limits delivering long-term survival benefits to most patients. We urgently need innovative, effective solutions that overcome the challenges of precision medicine. NUAgo Therapeutics, Inc. is pioneering a transformative approach that directly addresses these challenges. Born from over ten years of dedicated research at Northwestern University, our technology charts an entirely new course for the future of precision medicine by tackling the challenges of genetic variation. NUAgo Therapeutics offers a unique opportunity, combining a scientifically solid foundation with a leadership team having a clear strategic vision for addressing critical gaps in cancer treatment. Our technology is not just a new therapy; it's a new way of treating cancer, promising a significant impact on patient outcomes. We seek strategic partners and early-stage investors to support our pre-clinical studies targeting late 2025 / early 2026 IND submission. We invite investors to join us on this journey to transform cancer care and deliver substantial value to stakeholders and society.